Abatacept as a successful therapy for myositis—a case-based review

Clinical Rheumatology

Volumn 34, Issue 3, 2015, Pages 609-612

  Kerola, Anne M ^a,b   Kauppi, Markku J ^b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

Author keywords

Abatacept; Biologic therapy; Myositis; Necrotizing myopathy

Indexed keywords

ABATACEPT; ANTIRHEUMATIC AGENT;

CASE REPORT; FEMALE; HUMAN; MIDDLE AGED; MYOSITIS;

ABATACEPT; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; MIDDLE AGED; MYOSITIS;

EID: 84893174608     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2507-4     Document Type: Review

References (27)

1. Aggarwal R, Oddis CV (2012) Therapeutic advances in myositis. Curr Opin Rheumatol 24:635–641
2. Carstens PO, Schmidt J (2013) Diagnosis, pathogenesis and treatment of myositis: recent advances. Clin Exp Immunol.
3. Gordon PA, Winer JB, Hoogendijk JE, Choy EH (2012) Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev 8:CD003643
4. Couderc M, Gottenberg JE, Mariette X et al (2011) Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology (Oxford) 50:2283–2289
5. Majmudar S, Hall HA, Zimmermann B (2009) Treatment of adult inflammatory myositis with rituximab: an emerging therapy for refractory patients. J Clin Rheumatol 15:338–340
6. Garcia-Hernandez FJ, Gonzalez-Leon R, Castillo-Palma MJ, Sanchez-Roman J (2011) Rituximab is effective in the treatment of patients with idiopathic inflammatory myopathy. Clin Exp Rheumatol 29:363–364
7. Basnayake C, Cash K, Blumbergs P, Limaye V (2013) Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series. Clin Rheumatol.
8. Munoz-Beamud F, Isenberg DA (2013) Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies. Clin Exp Rheumatol 31:896–903
9. Oddis CV, Reed AM, Aggarwal R et al (2013) Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65:314–324
10. Muscle Study Group (2011) A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 70:427–436
11. Efthimiou P, Schwartzman S, Kagen LJ (2006) Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 65:1233–1236
12. Anandacoomarasamy A, Howe G, Manolios N (2005) Advanced refractory polymyositis responding to infliximab. Rheumatology (Oxford) 44:562–563
13. Hengstman GJ, van den Hoogen FH, Barrera P et al (2003) Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 50:10–15
14. Dastmalchi M, Grundtman C, Alexanderson H et al (2008) A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 67:1670–1677
15. Iannone F, Scioscia C, Falappone PC, Covelli M, Lapadula G (2006) Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 33:1802–1804
16. Lazarou IN, Guerne PA (2013) Classification, diagnosis, and management of idiopathic inflammatory myopathies. J Rheumatol 40:550–564
17. Dalakas MC, Rakocevic G, Schmidt J et al (2009) Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 132:1536–1544
18. Zong M, Dorph C, Dastmalchi M et al. (2013) Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis.
19. Okiyama N, Sugihara T, Iwakura Y, Yokozeki H, Miyasaka N, Kohsaka H (2009) Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum 60:2505–2512
20. Narazaki M, Hagihara K, Shima Y, Ogata A, Kishimoto T, Tanaka T (2011) Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford) 50:1344–1346
21. Higgs BW, Zhu W, Morehouse C et al (2014) A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 73:256–262
22. Iannone F, Lapadula G (2012) The inhibitor of costimulation of T cells: abatacept. J Rheumatol Suppl 89:100–102
23. Musuruana JL, Cavallasca JA (2011) Abatacept for treatment of refractory polymyositis. Joint Bone Spine 78:431–432
24. Arabshahi B, Silverman RA, Jones OY, Rider LG (2012) Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr 160:520–522
25. Murata K, Dalakas MC (1999) Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies. Am J Pathol 155:453–460
26. Nagaraju K, Raben N, Villalba ML et al (1999) Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol 92:161–169
27. the U.S. National Institutes of Health: ClinicalTrials.gov. Available at: www.clinicaltrials.gov. Accessed 23 Dec 2013